drugset
drugset / Trial / NCT01322802

Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer

NCT01322802 ↗

Phase 1 Completed 25 enrolled University of Washington National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects of vaccine therapy in treating patients with stage III-IV or recurrent ovarian cancer. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells.

Timeline

Start
2012-03-06
Primary completion
2015-01-09
Completion
2020-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject pUMVC3-hIGFBP-2 Vaccine — Other

Indications

ovarian carcinoma ovarian germ cell tumor